Compare AdaptHealth Corp (AHCO) vs Jabil Inc (JBL) Price & Performance

AdaptHealth Corp. (AHCO) trades at $5.74, up 9.96% in the last session, yet remains under pressure with a bearish technical signal and recent earnings misses. The company reported a Q2 2026 net loss of $228 million with a -6.82% margin, while selling its diabetes unit to focus on sleep and respiratory care. Valuation ratios show a low P/S of 0.23 and P/B of 0.55, but negative profitability metrics highlight operational challenges.

The outlook is mixed: analyst consensus is bullish with a $11 price target, but risks include ongoing losses, fraud investigations, and cost overruns in fixed-price contracts. Upside depends on successful business restructuring and margin improvement, while downside risks from legal and execution issues persist.

JBL trades at $368.37, up 9.43% with strong bullish momentum driven by AI infrastructure demand and recent earnings beats. The stock shows robust technical strength with moving averages signaling buy and price approaching resistance at $371. Fundamentally, revenue growth accelerated to $33.6B in 2026 with net profit margin improving to 2.56%, though valuation multiples remain elevated with P/E at 44.63.

Outlook remains positive with analyst consensus target of $448.29 (22% upside) and 50% buy ratings. Key opportunities include projected AI revenue growth to $20B+ by 2027, while risks include competitive pressures and the stock's premium valuation. Recent UBS upgrade to Buy highlights multi-year AI growth cycle potential.